Administration of an inhibitory peptide blocking SPIB–SPI1 interaction was efficient in suppressing glycolytic process, tumourigenesis and aggressiveness, indicating the oncogenic activities of SPIB/SPI1 in aerobic glycolysis and progression of cancer. The gene discussed is SPI1; the disease is cancer.